<PAGE>
Exhibit 10.1
AMENDMENT TO THE
DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT
BETWEEN
WYETH, ACTING THROUGH
ITS WYETH CONSUMER HEALTHCARE DIVISION,
AND
IMPAX LABORATORIES, INC.
This Amendment, effective as of February 14, 2005 (the
"Effective
Date"), to the Development, License and
Supply Agreement, dated as of June 1,
2002 and amended by letters dated November
19, 2002, April 23, 2003 and May 15,
2003 and amendment dated July 9, 2004, for
Loratadine/Pseudoephedrine
Combination Tablets (the "Agreement") is
entered into by and between Wyeth,
acting through its Wyeth Consumer
Healthcare Division (hereinafter called
"WCH"), and Impax Laboratories, Inc.
(hereinafter called "IMPAX").
PURPOSE
WHEREAS, under the Agreement, IMPAX has agreed to supply WCH with
D-24
Product (as defined in the Agreement);
WHEREAS, IMPAX and WCH wish to terminate the Agreement with respect
to
the D-24 Product only, all in accordance
with the terms and subject to the
conditions set forth in this Amendment.
NOW, THEREFORE, in consideration of the foregoing premises and
the
mutual covenants contained herein and
intending to be legally bound hereby, the
parties hereby agree as follows:
1. Unless
otherwise expressly defined herein, all capitalized terms
used herein shall have the same meaning as
defined
